ANGO vs MCTA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ANGO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
MCTA exhibits a severe disconnect between its market price and fundamental value, with a Piotroski F-Score of 6/9 indicating stable internal health but failing to justify a valuation that dwarfs its Graham Number ($0.07) and Intrinsic Value ($0.49). The company is trading at an astronomical Price-to-Book ratio of 9785.00 and a P/E of 419.36 despite a significant revenue contraction of 27% YoY. While gross margins are exceptionally high, negative operating margins and a current ratio of 0.59 signal poor operational efficiency and liquidity risks. The technical trend is heavily bearish, suggesting a speculative bubble that is currently deflating.
Compare Another Pair
Related Comparisons
ANGO vs MCTA: Head-to-Head Comparison
This page compares AngioDynamics, Inc. (ANGO) and Charming Medical Limited (MCTA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.